# US 2012/0252826 A1 · Combination Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252826 A1
- Document ID: US20120252826A1
- Status: Published application
- Kind: A1
- Application number: 13/282,750
- Filed: 2011-10-27
- Published: 2012-10-04
- Earliest claimed: 2003-02-13
- Assignees: AstraZeneca AB
- Inventors: Stephen Robert Wedge; Anderson Joseph Ryan
- Web page: https://patentgrep.com/patent/US20120252826A1

## CPC

- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises: the administration of ZD6474 in combination with 5-FU; ZD6474 in combination with CPT-11; or ZD6474 in combination with 5-FU and CPT-11.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

A pharmaceutical composition comprising
ZD6474 or a pharmaceutically acceptable salt thereof, and
at least one selected from the group consisting of 5-FU and CPT-11,
in association with a pharmaceutically acceptable excipient or carrier.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, comprising
ZD6474 or a pharmaceutically acceptable salt thereof, and
CPT-11,
in association with a pharmaceutically acceptable excipient or carrier.

### Claim 10 (depends on 8)

The pharmaceutical composition according to claim 8, comprising
ZD6474 or a pharmaceutically acceptable salt thereof, and
5-FU and CPT-11,
in association with a pharmaceutically acceptable excipient or carrier.

### Claim at position 5

11-13. (canceled)

### Claim 14

A method for the treatment of a cancer in a warm-blooded animal, which comprises administering to said animal in need thereof an effective amount of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline, also known as ZD6474:
or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of one of:
a.) 5-FU
b.) CPT-11; or
c.) 5-FU and CPT-11.

### Claim 15 (depends on 14)

The method of claim 14 wherein ZD6474 or a pharmaceutically acceptable salt thereof, is administered before, after or simultaneously with an effective amount of 5-FU.

### Claim 16 (depends on 15)

The method of claim 15 wherein the cancer is selected from a cancer of the colon, breast, prostate, lungs and skin.

### Claim 17 (depends on 15)

The method of claim 15 wherein the cancer is colorectal cancer.

### Claim 18 (depends on 15)

The method of claim 15 which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of 5-FU and before, after or simultaneously with an effective amount of ionising radiation.

### Claim 19 (depends on 14)

The method of claim 14 wherein ZD6474 or a pharmaceutically acceptable salt thereof, is administered before, after or simultaneously with an effective amount of CPT-11.

### Claim 20 (depends on 19)

The method of claim 19 wherein the cancer is selected from a cancer of the colon, breast, prostate, lungs and skin.

### Claim 21 (depends on 19)

The method of claim 19 wherein the cancer is colorectal cancer.

### Claim 22 (depends on 19)

The method of claim 19 which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of CPT-11 and before, after or simultaneously with an effective amount of ionising radiation.

### Claim 23 (depends on 14)

The method of claim 14 wherein ZD6474 or a pharmaceutically acceptable salt thereof, is administered before, after or simultaneously with an effective amount 5-FU and CPT-11.

### Claim 24 (depends on 23)

The method of claim 23 wherein the cancer is selected from a cancer of the colon, breast, prostate, lungs and skin.

### Claim 25 (depends on 23)

The method of claim 23 wherein the cancer is colorectal cancer.

### Claim 26 (depends on 23)

The method of claim 23 which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of 5-FU and CPT-11 and before, after or simultaneously with an effective amount of ionising radiation.

### Claim 27 (depends on 8)

The pharmaceutical composition according to claim 8, comprising ZD6474 or a pharmaceutically acceptable salt thereof, and 5-FU, in association with a pharmaceutically acceptable excipient or carrier.
